{"url_path":"/sec/atos/8-k/2026-06-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1488039/0001193125-26-266717-index.html","accession_number":"0001193125-26-266717","cik":"0001488039","ticker":"ATOS","issuer_name":"ATOSSA THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1488039/0001193125-26-266717-index.html","primary_entity_key":"0001488039","primary_entity_name":"ATOSSA THERAPEUTICS, INC."},"word_count":108,"has_tables":true,"body_markdown":"Item 9.01. Financial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\n \n\n \n\nExhibit No.\n\n \n\nDescription\n\n[4.1](atos-ex4_1.htm)\n\n \n\n[5.1](atos-ex5_1.htm)\n\n \n\n[10.1](atos-ex10_1.htm)\n\n \n\n23.1\n\n \n\nForm of Common Warrant\n\n \n\nOpinion of Gibson, Dunn & Crutcher LLP\n\n \n\nForm of Securities Purchase Agreement\n\n \n\nConsent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1)\n\n \n\n \n\n \n\n104\n\n \n\nCover page Interactive Data File (embedded within the Inline XBRL document)\n\n* * *\n\nSIGNATURES\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nAtossa Therapeutics, Inc.\n\nDate:\n\nJune 11, 2026\n\nBy:\n\n/s/ Mark J. Daniel\n\nMark J. Daniel\nChief Financial Officer\n\n(Principal Financial and Accounting Officer)"}